The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

CATEGORIES: General SLE | Skin

This Phase II, randomized, double-blind, placebo-controlled dose-ranging, parallel and adaptive study aims to evaluate the efficacy and safety of enpatoran in SLE and in CLE (SCLE and/or DLE) participants receiving standard of care (WILLOW).

To Learn More Contact:

EMD Serono US Medical Information at 888-275-7376 or email at

Communications Center by phone at +49 6151 72 5200 or email at identifier (NCT number): NCT05162586

Study to Evaluate BIIB059 in CLE With or Without SLE (LILAC)

First filed June 2016, verified Sept. 2020 - Completed


This multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study intends to evaluate the efficacy of BIIB059 in reducing skin disease activity in participants with systemic lupus erythematosus (SLE) (Part A), and in participants with active cutaneous lupus erythematosus (CLE) with or without systemic manifestations (Part B), and to investigate the dose response relationship in participants with active SLE and skin manifestations (Part A only).

Study sponsor: Biogen

To Learn More Contact identifier: NCT02847598

Learn More